Germany made drugmakers prove added benefit before insurers pay more

Before 2011, a new drug in Germany launched at whatever price its maker chose, and the statutory health insurers — covering most of the population — simply reimbursed it. The Pharmaceutical Market Restructuring Act (AMNOG) changed the sequence: new active ingredients still launch at a free price, but by six months after launch their price must be renegotiated on the basis of an early benefit assessment run by the G-BA, the committee that steers what the country's insurers reimburse.

The assessment asks one question: does the drug offer patients greater benefit than a comparable treatment already in use? The answer becomes the basis for price negotiations between the GKV-Spitzenverband, the insurers' association, and the manufacturer — structured as a rebate on the launch price. If the two sides cannot agree, an arbitration board sets the reimbursement price using European pricing levels as its standard. A drug rated without added benefit falls into the reference-price system within six months of launch.

Ten years of dossier data show the lever working. In the markets studied by Büssgen and Stargardt, negotiation cut the annual treatment cost of new psoriasis drugs from €20,601.59 to €16,763.57 — about 19% — though it remained well above the €5,178.00 cost of comparators. The design keeps launches fast, rewards real innovation with premium prices, and stops me-too drugs from charging innovation prices.

Free launch price, then pay only for proven benefit

Launch prices were set unilaterally by manufacturers while insurers had to reimburse them — the payer had no price lever at the moment it mattered.

Tying reimbursement to a benefit rating turns clinical evidence into the currency of pricing, so drugs that change outcomes earn premiums and me-too drugs cannot free-ride on them.

The six-month window keeps access fast: companies keep their free launch price while the assessment runs, so the process does not delay patient care.

Arbitration with European benchmarks caps the downside for both sides, keeping manufacturers willing to launch in Germany at all.

Separate access from pricing. Letting a product reach patients at once while its price is settled on evidence keeps access fast without giving the seller a permanent license to overcharge.

AMNOG's benefit assessment became the core of German drug pricing and one of the most studied pricing mechanisms in the world. Negotiated rebates became routine, and drugs rated without added benefit moved into reference pricing. The design drew international attention as a model of evidence-contingent pricing, and its building blocks — comparator-based benefit ratings, negotiation on the rating, arbitration in deadlock — prefigured Europe's later moves toward joint health-technology assessment.